Alto Neuroscience, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$66.4M | -$68.6M | -$37.8M |
| Operating expenses | $66.4M | $68.6M | $37.8M |
| Cash from operations | -$51.8M | -$47.4M | -$33.4M |
| Capital expenditure | $24,000 | $2.1M | $470,000 |
| Free cash flow | -$51.8M | -$49.5M | -$33.9M |
| Total assets | $184.7M | $177.5M | $86.6M |
| Total liabilities | $33.5M | $26.1M | $16.8M |
| Total debt | — | $10.0M | — |
Shares outstanding 35.1M · Free float 84.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.